

August 13, 2021

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE : 506285

SCRIP CODE : BAYERCROP

Dear Sir / Madam,

Sub.: Unaudited financial results of the Company for the quarter ended June 30, 2021 and Limited Review Report thereon

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to furnish the unaudited financial results of the Company for the quarter ended June 30, 2021 and the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

Kindly acknowledge receipt.

Thanking You.

Yours faithfully, for Bayer CropScience Limited

Nikunjkumar Savaliya

Company Secretary and Compliance Officer

Encl.: As above

Bayer CropScience Ltd. CIN: L24210MH1958PLC011173

Registered and Corporate Office: Bayer House Central Avenue Hiranandani Estate Thane (West) – 400 607 Maharashtra, India

Tel: +91 22 2531 1234 Fax: +91 22 2545 5063

www.bayer.in

www.cropscience.bayer.com

BAYER CROPSCIENCE LIMITED



Registered Office:

Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607 CIN L24210MH1958PLC011173

ART I ₹ in Millions					
FEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED J		UNE 30, 2021 Quarter Ended Year Ende			
				31.03.2021	
PARTICULARS	30.06.2021 UNAUDITED	31.03.2021 UNAUDITED	30.06.2020 UNAUDITED	AUDITED	
				_	
Revenue from Operations	14,159	7,337	12,278	42,613	
Other Income	148	159	149	638	
Total Income	14,307	7,496	12,427	43,251	
Expenses					
Cost of Materials Consumed	7,599	6,705	5,994	24,840	
Purchases of Stock-in-Trade	871	308	386	1,398	
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(608)	(2,947)	86	(1,779	
Employee Benefits Expense	1,070	967	938	3,622	
Finance Costs	25	35	27	126	
Depreciation and Amortisation Expense	146	216	237	735	
Other Expenses	2,004	1,477	1,621	6,415	
Total Expenses	11,107	6,761	9,289	35,357	
Profit Before Exceptional Items and Tax	3,200	735	3,138	7,894	
Add/ (Less): Exceptional Items (Note 3)					
- Employee separation expenses	-	63	(12)	51	
	-	63	(12)	51	
Profit Before Tax	3,200	798	3,126	7,945	
Tax Expense/ (Credit) (Note 4)					
- Current Tax	640	190	556	2,939	
- Deferred Tax	23	(11)	53	75	
Total Tax Expense	663	179	609	3,014	
Profit for the period/ year	2,537	619	2,517	4,931	
Other Comprehensive Income					
Items that will not be reclassified to profit or loss:					
- Remeasurement of Defined Benefit Obligation	4	75	-	32	
- Tax on remeasurement of Defined Benefit Obligation	(1)	(27)	-	(16	
Total Other Comprehensive Income	3	48	-	16	
Total Comprehensive Income for the period/ year	2,540	667	2,517	4,947	
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449	
Reserves (excluding Revaluation Reserve as per Balance Sheet)	-	-	-	25,054	
Earnings per share (basic and diluted) (*not annualised) in ₹	56.45*	13.77*	56.01*	109.72	
Paid up Equity Share Capital (Face Value ₹ 10/-) Reserves (excluding Revaluation Reserve as per Balance Sheet)	449	449	449		





BAYER CROPSCIENCE LIMITED



Registered Office:

Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607 CIN L24210MH1958PLC011173

NOTES:

- 1. The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.
- 2. The figures for the quarter ended March 31, 2021, are the balancing figures between audited figures for the financial year ended March 31, 2021 and the unaudited published year to date figures upto the third quarter of the previous financial year, which were subjected to limited review.
- 3. Exceptional item consists of expense in relation to separation of employees arising from restructuring measures due to amalgamation of Monsanto India Limited with Bayer CropScience Limited and Bayer 2022 global efficiency program.
- **4.** In respect of certain past years, with a view to give certainty and effectively close long pending disputes and litigations under the Income Tax Act, 1961, the Company had filed an application under The Direct Tax Vivad Se Vishwas Act, 2020 (VSV Act) and related rules. Consequent to tax authority's order under VSV Act in December 2020, an additional tax expense of ₹1,272 Million (net) was recognized in year ended March 2021. The effect of this tax expense on the Profit After Tax for the said period was disclosed below:

	₹ in Millions
	Year
PARTICULARS	Ended
	31.03.2021
Profit after Tax	4,931
Add: Current tax related to prior period arising under VSV Act	1,272
Profit after Tax, before Tax Expense related to VSV Act	6,203

- 5. The Management has considered the possible effects, if any, that may result from COVID-19 pandemic on the carrying amounts of current assets after considering internal and external sources of information as at the date of approval of these financial results. Given the uncertainties associated with pandemic's nature and duration, the actuals may differ from the estimates considered in these financial statements.
- **6.** The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 13, 2021. The above results have been subjected to limited review by the Statutory Auditors of the Company.

By Order of the Board

Rolf Hoffmann Executive Director & Chief Financial Officer DIN 08460583

Place: Obermaiselstein, Germany Date: August 13, 2021





Deloitte Haskins & Sells LLP

Chartered Accountants Indiabulis Finance Centre Tower 3, 27°-32° Floor Senapati Bapat Marg Elphinstone Road (West) Mumbai - 400 013 Maharashtra, India

Tel: +91 22 6185 4000 Fax: +91 22 6185 4001

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED

- 1. We have reviewed the Unaudited Financial Results of **BAYER CROPSCIENCE LIMITED** ("the Company"), for the quarter ended June 30, 2021 included in the accompanying Statement of Unaudited Financial Results ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Deloitte Haskins & Sells LLP

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)

Sampada S Narvankar (Partner) (Membership No. 102911) (UDIN: 21102911AAAADH9531)

Place: MUMBAI

Date: August 13, 2021